Mechanism of action of anti-TNF therapy in inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 10, Issue 8, 2016, Pages 989-997

  Levin, Alon D ^a   Wildenberg, Manon E ^a   van den Brink, Gijs R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adalimumab; Anti TNF; Apoptosis; Certolizumab; Crohn's; Infliximab; Macrophage; Mucosal healing; T cell; Wound healing

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; FC RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; ADALIMUMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR;

APOPTOSIS; BIOCHEMICAL ANALYSIS; CELL MEDIATED CYTOTOXICITY; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LAMINA PROPRIA; MACROPHAGE; PRIORITY JOURNAL; PROTEIN SECRETION; REMISSION; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; WOUND HEALING; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; DRUG EFFECTS; GASTROINTESTINAL ENDOSCOPY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BIOMARKERS; CERTOLIZUMAB PEGOL; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INTESTINAL MUCOSA; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 85010942490     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw053     Document Type: Review

References (67)

1. Dube PE, Punit S, Polk DB. Redeeming an old foe: Protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2015;308:G161-70
2. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 2016;12:49-62
3. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104:487-501
4. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4
5. Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin [tumor necrosis factor]. Immunol Lett 1985;11:173-7
6. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71
7. van der Poll T, Levi M, van Deventer SJ, et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994;83:446-51
8. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4
9. KojouharoffG, Hans W, Obermeier F, et al. Neutralization of tumour necrosis factor [TNF] but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997;107:353-8
10. Noti M, Corazza N, Mueller C, Berger B, Brunner T. TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med 2010;207:1057-66
11. Hale LP, Greer PK. A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features. PLoS One 2012;7:e41797
12. Dayer Schneider J, Seibold I, Saxer-Sekulic N, et al. Lack of TNFr2 expression by CD4[+] t cells exacerbates experimental colitis. Eur J Immunol 2009;39:1743-53
13. Chen X, Wu X, Zhou Q, et al. TNFr2 is critical for the stabilization of the CD4+foxp3+ regulatory T cell phenotype in the inflammatory environment. J Immunol 2013;190:1076-84
14. Housley WJ, Adams CO, Nichols FC, et al. Natural but not inducible regulatory T cells require TNF-alpha signalling for in vivo function. J Immunol 2011;186:6779-87
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The accent I randomised trial. Lancet 2002;359:1541-9
16. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody [adalimumab] in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591
17. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody CA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease CA2 study group. N Engl J Med 1997;337:1029-35
18. Cote-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P. Biologics in inflammatory bowel disease: What are the data? United European Gastroenterol J 2015;3:419-28
19. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'etude thérapeutique des affections inflammatoires digestives. Gastroenterology 1990;98:811-8
20. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95
21. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012;142:1102-11.e2
22. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
23. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn's disease: A placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9:670-8.e3
24. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
25. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDp571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: A randomised, double blind, placebo controlled trial. Gut 2004;53:1485-93
26. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
27. Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate-tosevere Crohn's disease: A randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:888-93
28. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease [SES-CD] than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9
29. Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn's disease activity: Comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010;16:2131-6
30. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: Monitoring disease activity. Aliment Pharmacol Ther 2003;17[Suppl 2]:11-7
31. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'etudes thérapeutiques des affections inflammatoires digestives. Gut 1994;35:231-5
32. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease [STRIDE]: Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324-38
33. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8; quiz e10-1
34. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: A systematic review. Inflamm Bowel Dis 2013;19:429-44
35. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301
36. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42; quiz 64
37. Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8
38. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47
39. Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: A French retrospective study. Rheumatology [Oxford] 2010;49:1694-8
40. Krishnan A, Stobaugh DJ, Deepak P. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int 2015;35:661-8
41. Toussirot é, Houvenagel é, Goëb V, et al. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: A nationwide series. Joint Bone Spine 2012;79:457-63
42. van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441-6
43. Upadhyay V, Fu YX. Lymphotoxin signalling in immune homeostasis and the control of microorganisms. Nat Rev Immunol 2013;13:270-9
44. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997;61:375-80
45. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11
46. Van den Brande JMH, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007;56:509-17
47. Atreya R, Zimmer M, Bartsch B, et al. Antibodies against tumor necrosis factor [TNF] induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14? macrophages. Gastroenterology 2011;141:2026-38
48. Van den Brande JMH, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85
49. Vos ACW, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc regiondependent manner. Gastroenterology 2011;140:221-30
50. Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009;45:124-31
51. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-16
52. Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology 2004;126:934-5; author reply 5-6
53. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol [CDp870]: In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
54. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent antiinflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376-92
55. Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis 2013;19:1224-31
56. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57
57. Ringheanu M, Daum F, Markowitz J, et al. Effects of infliximab on apoptosis and reverse signalling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004;10:801-10
58. Caprioli F, Bose F, Rossi RL, et al. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. Inflamm Bowel Dis 2013;19:729-39
59. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6: 443-6
60. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: Comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248-57
61. Vos ACW, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 2012;18:401-8
62. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
63. McRae BL, Levin AD, Wildenberg ME, et al. Fc receptor-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of inflammatory bowel disease. J Crohns Colitis 2016;10:69-76
64. Moroi R, Endo K, Kinouchi Y, et al. Fcgr3a-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 2013;65:265-71
65. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IGg Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004;19:511-9
66. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IGg Fc receptor gene FCGR3a and response to infliximab in Crohn's disease: A subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006;16:911-4
67. Biancheri P, Brezski RJ, Di Sabatino A, et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 2015;149:156474